Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Shares Outstanding (Diluted Average) (2022 - 2026)

Indivior Pharmaceuticals has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $129.0 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) rose 3.2% year-over-year to $129.0 million; the TTM value through Mar 2026 reached $129.0 million, up 3.2%, while the annual FY2025 figure was $128.0 million, 3.76% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $129.0 million at Indivior Pharmaceuticals, up from $128.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $139.0 million in Q4 2022 and troughed at $310.0 in Q1 2023.
  • A 5-year average of $82.4 million and a median of $127.0 million in 2025 define the central range for Shares Outstanding (Diluted Average).
  • On a YoY basis, Shares Outstanding (Diluted Average) climbed as much as 44193448.39% in 2024 and fell as far as 57.14% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $139.0 million in 2022, then decreased by 1.44% to $137.0 million in 2023, then fell by 2.92% to $133.0 million in 2024, then dropped by 3.76% to $128.0 million in 2025, then rose by 0.78% to $129.0 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for INDV at $129.0 million in Q1 2026, $128.0 million in Q4 2025, and $129.0 million in Q3 2025.